You are here
Friday, December 22, 2017
Zika remains a research and public health challenge, say NIAID scientists
Since 2016, when Zika was declared by WHO as a public health emergency of international concern, the virus has become established in more than 80 countries, infected millions of people, and left many babies with birth defects (collectively called congenital Zika syndrome). Although scientists have made progress in their understanding of the virus and its mosquito carrier, and are working toward treatments and a preventive vaccine, it would be premature to think that the Zika pandemic is now under control and will not reemerge, perhaps more aggressively, say leaders from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The Journal of Infectious Diseases published online December 16 a special supplement of articles examining current scientific knowledge about the Zika virus and the key research questions that remain. The supplement was sponsored and edited by NIAID and features several articles written by NIAID scientists.
The journal’s introductory article was written by NIAID director Anthony S. Fauci, M.D., and senior advisor David Morens, M.D. It notes some of the critical scientific questions regarding Zika that deserve further exploration, including: whether certain viral mutations occurred to facilitate its geographical spread; if different species of Aedes mosquitoes are capable of transmitting Zika and what that may mean for future transmission; what is apparently unique to Zika compared to other more well-known flaviviruses, such as dengue, that can explain why it can cause congenital infections, neurological conditions and encephalitis, transmit sexually and persist for long periods of time in multiple parts of the human body; and whether preexisting immunity to other related flaviviruses may impact Zika exposure and infection.
Some of the severe manifestations and complications associated with Zika disease include fetal loss, microcephaly and other birth defects, and the potential for delayed mental and physical effects among infected babies born in apparent good health. These factors represent a “profound medical tragedy” and societal challenge that will require decades of financial, medical and social support, Drs. Fauci and Morens write. They note that the rubella epidemic of the 1960s, when tens of thousands of babies were born with congenital rubella syndrome in the United States, can provide important lessons learned that may be directly applicable to Zika research. The Zika pandemic is likely to serve as a roadmap for addressing future emerging infectious disease challenges, the authors conclude.
Morens, DM and Fauci, AS. Pandemic Zika: A formidable challenge to medicine and public health. The Journal of Infectious Diseases DOI: 10.1093/infdis/jix383 (2017).
NIAID Director Anthony S. Fauci, M.D., is available for comment.
To schedule interviews, please contact Elizabeth Deatrick, (301) 402-1663, firstname.lastname@example.org.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®